Table S1 Clinical data and multiple regression analysis of metastatic LAPC patients treated with gem-based regimen by multivariable analysis

Baseline characteristics	Patients number	GemciTest classification		Univariate		Multivariate	
		Negative	Positive	P^{OS}	P^{PFS}	P^{OS}	P^{PFS}
Number	43	30	13				
Comp1	43			6.71E–02	0.4062	–	–
Comp2	43			0.203	0.02	–	0.002
Gender (female)	20 (46%)	14 (70%)	6 (30%)	0.843	0.809	–	–
Age (years), median (range)	74 (53.0–85.0)	75.0 (58.0–85.0)	71.5 (53.0–79.0)	0.091	0.952	–	–
Body mass index, mean (SD)	23.0 (3.6)	22.8 (3.5)	23.5 (3.9)	0.95	0.734		
Geographical region				–	–	–	–
France	37 (86%)	27(90%)	10(77%)				
US	5 (12%)	3 (10%)	2 (15%)				
Czech Rep	0 (0%)	0 (0%)	0 (0%)				
Romania	1 (2%)	0 (0%)	1 (8%)				
Poland	0 (0%)	0 (0%)	0 (0%)				
CA 19–9 (U/mL), mean (SD)	1,865 [7,978]	2,459 [9,835]	769 [1,874]	0.123	0.78	–	–
Albumin (g/L), mean (SD)	35.1 (7.9)	35.2 (9.3)	34.8 (4.8)	0.00542	0.0674	0.001	–
QLQ–C30 Global, mean (SD)	57.3 (15.1)	58.8 (17.7)	56.4 (14.6)	–	–	–	–
ECOG PS				0.001	0.116	0.002	–
ECOG [0–1]	33 (76%)	20 (66%)	13 (100%)				
ECOG [2+]	10 (24%)	10 (34%)	0 (0%)				
Monocyte count (per µL), median (range)	0.55 (0.0–0.93)	0.60 (0.0–0.93)	0.55 (0.2–0.80)	–	–	–	–
Tumor localization[‡]							
Head	25 (58%)	15 (55%)	10 (66%)	0.823	0.2495	–	–
Body	15 (34%)	11 (40%)	4 (26%)	0.4	0.207	–	–
Tail	2 (8%)	1 (5%)	1 (8%)	0.106	0.001	–	0.002

Unless stated otherwise, data are the number of patients (%). [‡], patients presenting tumors in more than one location are included in both categories. LAPC, locally advanced PDAC; P, P value; Comp1 and Comp2, gene-set component 1 and 2; CA19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperative Oncology Group Performance Status; SD, standard deviation.

Table S2 Clinical data and multiple regression analysis of metastatic PDAC patients treated with 5FU-based regimen by multivariable analysis

Baseline characteristics	Patients number	GemciTest classification		Univariate		Multivariate	
		Negative	Positive	P^{OS}	P^{PFS}	P^{OS}	P^{PFS}
Number	59	54	5				
Comp1				0.98	0.37	–	–
Comp2				0.85	0.32	–	–
Gender (female)	28 (48%)	25 (46%)	3 (60%)	0.98	0.85	–	–
Age (years), median (range)	66.0 (44.0–78.0)	65.5 (44.0–78.0)	68.0 (62.0–71.0)	0.15	0.55	–	–
Body mass index, mean (SD)	27.2 (29.2)	27.8 (30.6)	22.2 (5.0)	0.82	0.36	–	–
Geographical region							
France	59 (100%)	54 (100%)	5 (100%)				
US	0 (0%)	0 (0%)	0 (0%)				
Czech Rep	0 (0%)	0 (0%)	0 (0%)				
Romania	0 (0%)	0 (0%)	0 (0%)				
Poland	0 (0%)	0 (0%)	0 (0%)				
CA 19-9 (U/mL), mean (SD)	38,540 [71,993]	41,686 [74,351]	2,887 [2,025]	0.06	0.25	–	–
Albumin (g/L), mean (SD)	37.1 (6.5)	36.9 (6.8)	38.8 (2.5)	0.08	0.02	–	0.004
ECOG PS				0.01	0.01	0.04	0.23
ECOG [0–1]	41 (70%)	36 (67%)	5 (100%)				
ECOG [2–4]	15 (30%)	15 (33%)	0 (0%)				
Monocyte count (per µL), median (range)	0.69 (0.38–1.85)	0.69 (0.38–1.85)	0.77 (0.60–0.93)				
Tumor localization‡							
Head	18 (31%)	15 (28%)	3 (60%)	0.09	0.04	–	0.84
Body	22 (37%)	20 (37%)	2 (40%)	0.89	0.74	–	–
Tail	22 (37%)	22 (41%)	0 (0%)	0.004	0.01	0.030	0.05

Unless stated otherwise, data are the number of patients (%). ‡, patients presenting tumors in more than one location are included in both categories. PDAC, pancreatic ductal adenocarcinoma; P, P value; Comp1 and Comp2, gene-set component 1 and 2; CA19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperative Oncology Group Performance Status; SD, standard deviation.